Trav13d-3 Inhibitors
Trav13d-3 inhibitors are a class of chemical compounds that specifically target and modulate the activity of the Trav13d-3 protein or receptor. These inhibitors function by binding to the active site of the Trav13d-3 protein, preventing the natural substrate or ligand from interacting with the protein and thereby disrupting its biological function. In addition to binding at the active site, some Trav13d-3 inhibitors may also act on allosteric sites, which are regions of the protein located away from the active site. When inhibitors bind to these allosteric sites, they can induce conformational changes in the protein structure, diminishing or halting the protein's functional capabilities. The interactions between Trav13d-3 inhibitors and the protein are often stabilized by non-covalent forces, such as hydrogen bonds, van der Waals forces, hydrophobic interactions, and electrostatic forces, which together enhance the inhibitor's binding affinity and specificity.
Structurally, Trav13d-3 inhibitors exhibit considerable diversity, with designs ranging from small organic molecules to more complex chemical frameworks. Key structural elements of these inhibitors often include aromatic rings, heterocycles, and functional groups like hydroxyl, amine, or carboxyl groups, which are essential for interacting with specific residues in the Trav13d-3 protein's binding pocket. These functional groups allow the inhibitors to engage in important non-covalent interactions, such as hydrogen bonding or π-stacking with aromatic residues, which contribute to the stability of the inhibitor-protein complex. The design of these inhibitors also takes into account important physicochemical properties, such as molecular weight, solubility, polarity, and lipophilicity, to optimize their stability and functionality in various biological environments. Hydrophobic regions within the inhibitors often interact with non-polar areas of the protein, while polar or charged functional groups enable interactions with polar residues, further enhancing the overall binding efficacy. Through careful tuning of these structural features, Trav13d-3 inhibitors can be tailored for strong and selective modulation of the Trav13d-3 protein's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. Trav13d-3, being a protein with potential kinase activity, can be inhibited by staurosporine through its action of blocking the ATP binding site, thus preventing phosphorylation events that Trav13d-3 might catalyze. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a specific inhibitor of phosphoinositide 3-kinases (PI3K). If Trav13d-3 is involved in a pathway downstream of PI3K signaling, its activity would be inhibited as a result of the disruption of the PI3K-dependent signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another specific inhibitor of PI3K. Similar to wortmannin, it prevents PI3K from phosphorylating downstream targets, which could include Trav13d-3, leading to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of several signaling pathways. Inhibition of MEK could result in the inhibition of Trav13d-3 if it is a part of MAPK/ERK pathway signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, the signaling pathways that rely on JNK's kinase activity, possibly including those involving Trav13d-3, would be inhibited. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. If Trav13d-3 functions downstream of p38 MAP kinase in a signal transduction pathway, the inhibition of p38 MAP kinase activity would lead to the inhibition of Trav13d-3 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, similar to PD98059. It functions by inhibiting the activation of ERK1/2. If Trav13d-3 operates within the MEK/ERK pathway, its function would be inhibited by U0126 through the suppression of ERK1/2 activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. As mTOR is a central regulator of cell growth and proliferation, its inhibition could lead to the inhibition of downstream proteins like Trav13d-3 if they are involved in mTOR signaling pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor. If Trav13d-3 is involved in a signaling pathway that is regulated by Src kinase activity, its function would be inhibited by PP2 through the inhibition of Src kinase activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor. By inhibiting tyrosine kinases, it potentially inhibits the activity of Trav13d-3 if Trav13d-3's function is dependent on tyrosine phosphorylation. | ||||||